Core Viewpoint - The low molecular weight heparin (LMWH) market in China is experiencing steady growth, driven by advancements in medical technology and increasing clinical applications, with a projected market size of approximately 68.07 billion yuan in 2024 and 69.29 billion yuan in 2025 [1][5]. Group 1: Market Size and Structure - The LMWH market in China is expected to reach 68.07 billion yuan in 2024, with the following market share distribution: dalteparin sodium injection (15.47%), low molecular weight heparin calcium injection (7.01%), nadroparin calcium injection (18.22%), enoxaparin sodium injection (26.77%), and other LMWH preparations (32.54%) [1][5]. - By 2025, the market size is projected to be around 69.29 billion yuan, with similar distribution trends among the various LMWH products [1][5]. Group 2: Industry Development and Trends - The LMWH industry has evolved significantly since the discovery of heparin in the early 20th century, with key milestones including the commercialization of heparin in 1938 and the introduction of nadroparin in 1978 [3]. - The Chinese LMWH industry has undergone three stages: crude product export, industrial enhancement, and the establishment of a complete industrial chain [3]. - The global LMWH market is also growing, with a projected increase from 4.334 billion USD in 2020 to 5.876 billion USD in 2024, and an expected market size of 6.2 billion USD in 2025 [4]. Group 3: Production and Demand - The production of LMWH in China is on the rise, with an estimated output of 36,327 million doses in 2024, up from 17,367 million doses in 2020, and expected to exceed 40,000 million doses in 2025 [6][7]. - The demand for LMWH in China is projected to reach approximately 42,523 million doses by 2025, reflecting a growing need for these anticoagulants in clinical settings [5][6]. Group 4: Competitive Landscape - Major companies in the Chinese LMWH market include Jiuyuan Gene, Hongri Pharmaceutical, Chenxin Pharmaceutical, and others, with a concentration of production in eastern coastal regions such as Jiangsu, Shandong, and Guangdong [8]. - In 2024, the market share of imported LMWH products remains above 20%, with notable sales figures for domestic products, including 3.42 billion yuan for Sanofi's enoxaparin sodium injection and 4.12 billion yuan for Qilu Pharmaceutical's LMWH sodium injection [8][9]. Group 5: Technological Advancements - The production technology for LMWH has advanced significantly, moving from traditional chemical degradation methods to modern biotechnological approaches, enhancing product purity and reducing production costs [9][10]. - Future trends in the LMWH industry include a focus on high-efficiency, green, and intelligent production methods, as well as the development of customized LMWH products in response to the rise of personalized medicine [11][12].